Spectrum and clinical relevance of PALB2 germline mutations in 7657 Chinese BRCA1/2-negative breast cancer patients
Authors:
- 25 November 2019
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 179 (3) , 605-614
Abstract
To investigate the prevalence and clinical relevance of PALB2 germline mutations in BRCA1/2-negative breast cancer patients.Keywords
Funding Information
- National Natural Science Foundation of China (81772824)
- Science Foundation of Peking University Cancer Hospital (2017-8)
This publication has 40 references indexed in Scilit:
- Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencingProceedings of the National Academy of Sciences, 2011
- PALB2 mutations in German and Russian patients with bilateral breast cancerBreast Cancer Research and Treatment, 2010
- A PALB2 germline mutation associated with hereditary breast cancer in ItalyFamilial Cancer, 2009
- PALB2 is an integral component of the BRCA complex required for homologous recombination repairProceedings of the National Academy of Sciences, 2009
- Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility GeneScience, 2009
- PALB2 Links BRCA1 and BRCA2 in the DNA-Damage ResponseCurrent Biology, 2009
- Penetrance Analysis of the PALB2 c.1592delT Founder MutationClinical Cancer Research, 2008
- Analysis ofPALB2/FANCN-associated breast cancer familiesProceedings of the National Academy of Sciences, 2007
- A recurrent mutation in PALB2 in Finnish cancer familiesNature, 2007
- PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility geneNature Genetics, 2006